Suppr超能文献

不稳定铁在肾脏疾病中的作用及螯合治疗

The role of labile iron in kidney disease and treatment with chelation.

作者信息

Shah Sudhir V, Rajapurkar Mohan M

机构信息

Division of Nephrology, Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.

出版信息

Hemoglobin. 2009;33(5):378-85. doi: 10.3109/03630260903212233.

Abstract

There are two major forms of kidney disease: acute renal failure [also referred to as acute kidney injury (AKI)] and chronic kidney disease (CKD). Acute renal failure is an abrupt loss of kidney function within 48 h, whereas CKD is a loss of kidney function greater than 3 months. There is a large amount of experimental evidence for an increase of labile iron in a wide variety of models of kidney disease. Additionally, iron chelators provide protection, indicating an important role of labile iron in these diseases. These observations suggest that iron chelators may provide a new modality of prevention and treatment of kidney disease.

摘要

肾脏疾病主要有两种形式

急性肾衰竭[也称为急性肾损伤(AKI)]和慢性肾脏病(CKD)。急性肾衰竭是指在48小时内肾功能突然丧失,而慢性肾脏病是指肾功能丧失超过3个月。在多种肾脏疾病模型中,有大量实验证据表明不稳定铁增加。此外,铁螯合剂具有保护作用,表明不稳定铁在这些疾病中起重要作用。这些观察结果表明,铁螯合剂可能为肾脏疾病的预防和治疗提供一种新的方式。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验